{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:22:49Z","timestamp":1769502169691,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T00:00:00Z","timestamp":1623456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Wayne B. Duddlesten Professorship in Cancer Research"},{"name":"Raymond and Maria Floyd Bladder Cancer Research Foundation Grant"},{"name":"NIH\/NCI UTMD Anderson SPORE in Genitourinary Cancer","award":["P50CA091846"],"award-info":[{"award-number":["P50CA091846"]}]},{"name":"Cancer Center Support Grant","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00345-021-03755-w","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T12:03:27Z","timestamp":1623499407000},"page":"4143-4149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center"],"prefix":"10.1007","volume":"39","author":[{"given":"Kelly K.","family":"Bree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Matulay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graciela M.","family":"Nogueras-Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neema","family":"Navai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin P.","family":"Dinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,12]]},"reference":[{"issue":"1","key":"3755_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"10061","key":"3755_CR2","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Hahn NM, Efstathiou JA et al (2016) Bladder cancer. Lancet 388(10061):2796\u20132810","journal-title":"Lancet"},{"issue":"2","key":"3755_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.eururo.2015.08.037","volume":"69","author":"J Dobruch","year":"2016","unstructured":"Dobruch J, Daneshmand S, Fisch M et al (2016) Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 69(2):300\u2013310","journal-title":"Eur Urol"},{"issue":"1","key":"3755_CR4","doi-asserted-by":"publisher","first-page":"40.e23","DOI":"10.1016\/j.urolonc.2013.04.010","volume":"32","author":"H Donsky","year":"2014","unstructured":"Donsky H, Coyle S, Scosyrev E, Messing EM (2014) Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol Oncol 32(1):40.e23\u201331","journal-title":"Urol Oncol"},{"issue":"5","key":"3755_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2013.11.040","volume":"66","author":"LA Kluth","year":"2014","unstructured":"Kluth LA, Rieken M, Xylinas E et al (2014) Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 66(5):913\u2013919","journal-title":"Eur Urol"},{"issue":"5","key":"3755_CR6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.eururo.2007.10.006","volume":"53","author":"J Fernandez-Gomez","year":"2008","unstructured":"Fernandez-Gomez J, Solsona E, Unda M et al (2008) Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53(5):992\u20131001","journal-title":"Eur Urol"},{"issue":"1","key":"3755_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2011.10.029","volume":"62","author":"J Palou","year":"2012","unstructured":"Palou J, Sylvester RJ, Faba OR et al (2012) Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol 62(1):118\u2013125","journal-title":"Eur Urol"},{"issue":"5","key":"3755_CR8","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/00365590802016302","volume":"42","author":"G Jancke","year":"2008","unstructured":"Jancke G, Damm O, Rosell J, Jahnson S (2008) Risk factors for local recurrence in patients with pTa\/pT1 urinary bladder cancer. Scand J Urol Nephrol 42(5):417\u2013421","journal-title":"Scand J Urol Nephrol"},{"issue":"16","key":"3755_CR9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, Bohle A et al (2016) Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol 34(16):1935\u20131944","journal-title":"J Clin Oncol"},{"key":"3755_CR10","unstructured":"Babjuk M, Burger M, Comp\u00e9rat E, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Roupr\u00eat M, Shariat SF, Sylvester R (2021) EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). https:\/\/uroweb.org\/guideline\/non-muscle-invasive-bladder-cancer\/. Accessed 5 July 2021"},{"issue":"5","key":"3755_CR11","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 182(5):2195\u20132203","journal-title":"J Urol"},{"issue":"6","key":"3755_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.euf.2017.08.007","volume":"4","author":"A Uhlig","year":"2018","unstructured":"Uhlig A, Strauss A, Hosseini ASM et al (2018) Gender-specific differences in recurrence of non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4(6):924\u2013936","journal-title":"Eur Urol Focus"},{"issue":"19","key":"3755_CR13","doi-asserted-by":"publisher","first-page":"27325","DOI":"10.18632\/oncotarget.8756","volume":"7","author":"Z Shang","year":"2016","unstructured":"Shang Z, Li Y, Hsu I et al (2016) Targeting estrogen\/estrogen receptor alpha enhances bacillus Calmette-Guerin efficacy in bladder cancer. Oncotarget 7(19):27325\u201327335","journal-title":"Oncotarget"},{"issue":"3","key":"3755_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466\u2013475 (discussion 475\u2013477)","journal-title":"Eur Urol"},{"issue":"3","key":"3755_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","volume":"106","author":"SA Boorjian","year":"2010","unstructured":"Boorjian SA, Zhu F, Herr HW (2010) The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 106(3):357\u2013361","journal-title":"BJU Int"},{"issue":"1","key":"3755_CR16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","volume":"67","author":"P Gontero","year":"2015","unstructured":"Gontero P, Sylvester R, Pisano F et al (2015) Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus Calmette-Guerin: results of a retrospective multicenter study of 2451 patients. Eur Urol 67(1):74\u201382","journal-title":"Eur Urol"},{"issue":"6","key":"3755_CR17","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1097\/01.ju.0000181799.81119.fc","volume":"174","author":"HW Herr","year":"2005","unstructured":"Herr HW (2005) Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 174(6):2134\u20132137","journal-title":"J Urol"},{"issue":"4","key":"3755_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"key":"3755_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euf.2019.06.001","volume":"7","author":"MJ Krimphove","year":"2019","unstructured":"Krimphove MJ, Szymaniak J, Marchese M et al (2019) Sex-specific differences in the quality of treatment of muscle-invasive bladder cancer do not explain the overall survival discrepancy. Eur Urol Focus 7:124\u2013131","journal-title":"Eur Urol Focus"},{"issue":"5","key":"3755_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.euo.2020.08.013","volume":"3","author":"M Koti","year":"2020","unstructured":"Koti M, Ingersoll MA, Gupta S et al (2020) Sex differences in bladder cancer immunobiology and outcomes: a collaborative review with implications for treatment. Eur Urol Oncol 3(5):622\u2013630","journal-title":"Eur Urol Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03755-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03755-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T15:05:52Z","timestamp":1636124752000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03755-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,12]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3755"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03755-w","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,12]]},"assertion":[{"value":"5 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KK Bree: Stratify genomics\u2014consultant; CP Dinney: National Cancer Institutes research funding, University of East Finland Faculty of Health Sciences (UEFHS) research funding, grant and personal fees from FKD Therapies, creator of intellectual property owned by UT\/MDACC related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovac. AM Kamat: personal fees and other from Merck, personal fees from Abbott Molecular, personal fees from Arquer, personal fees from ArTara, personal fees from Asieris, personal fees and other from Photocure, personal fees from Astra Zeneca, personal fees from BioClin Therapeutics, personal fees and other from BMS, personal fees from Cepheid, personal fees from Cold Genesys, other from FKD Industries, personal fees from Eisai, personal fees from Engene, Inc., personal fees from Ferring, personal fees from FerGene, personal fees from Imagin, personal fees from Janssen, personal fees from MDxHealth, personal fees from Medac, personal fees from Pfizer, personal fees from Roviant, personal fees from Sessen Bio, personal fees from ProTara, personal fees from Nucleix, personal fees from Seattle Genetics, grants from CEC Oncology, personal fees from Theralase, personal fees from TMC Innovation, personal fees from US Biotest, other from Adolor, other from Heat Biologics, patent for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy pending.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study had been approved by the competent ethics committee (2017\u201302257) and all applicable institutional and governmental regulations concerning the ethical use of the data were followed. All data were encrypted and kept confidential.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Waiver of consent granted given retrospective nature of review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}